Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H23F3N6O.2ClH |
Molecular Weight | 505.364 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.COC1=CC=C(C=C1CN[C@H]2CCCN[C@H]2C3=CC=CC=C3)N4N=NN=C4C(F)(F)F
InChI
InChIKey=YVNRXILPJNISEM-FFUVTKDNSA-N
InChI=1S/C21H23F3N6O.2ClH/c1-31-18-10-9-16(30-20(21(22,23)24)27-28-29-30)12-15(18)13-26-17-8-5-11-25-19(17)14-6-3-2-4-7-14;;/h2-4,6-7,9-10,12,17,19,25-26H,5,8,11,13H2,1H3;2*1H/t17-,19-;;/m0../s1
Molecular Formula | C21H23F3N6O |
Molecular Weight | 432.4421 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Vofopitant (previously known as GR205171), a tetrazole-derivative, was developed as a neurokinin1 receptor antagonist. Vofopitant was studied in clinical trials phase II for the treatment of primary insomnia and posttraumatic stress disorder. However, these studies were discontinued due to lack of effectiveness. In addition, vofopitant participated in phase I for patients with bipolar disorder. However, this study was terminated because of the slow recruitment; trial unlikely to reach completion.
Originator
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:58:05 GMT 2023
by
admin
on
Fri Dec 15 15:58:05 GMT 2023
|
Record UNII |
53187BIJ00
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C267
Created by
admin on Fri Dec 15 15:58:05 GMT 2023 , Edited by admin on Fri Dec 15 15:58:05 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL522302
Created by
admin on Fri Dec 15 15:58:05 GMT 2023 , Edited by admin on Fri Dec 15 15:58:05 GMT 2023
|
PRIMARY | |||
|
6918330
Created by
admin on Fri Dec 15 15:58:05 GMT 2023 , Edited by admin on Fri Dec 15 15:58:05 GMT 2023
|
PRIMARY | |||
|
168266-51-1
Created by
admin on Fri Dec 15 15:58:05 GMT 2023 , Edited by admin on Fri Dec 15 15:58:05 GMT 2023
|
PRIMARY | |||
|
C152903
Created by
admin on Fri Dec 15 15:58:05 GMT 2023 , Edited by admin on Fri Dec 15 15:58:05 GMT 2023
|
PRIMARY | |||
|
DTXSID00168538
Created by
admin on Fri Dec 15 15:58:05 GMT 2023 , Edited by admin on Fri Dec 15 15:58:05 GMT 2023
|
PRIMARY | |||
|
53187BIJ00
Created by
admin on Fri Dec 15 15:58:05 GMT 2023 , Edited by admin on Fri Dec 15 15:58:05 GMT 2023
|
PRIMARY | |||
|
LL-36
Created by
admin on Fri Dec 15 15:58:05 GMT 2023 , Edited by admin on Fri Dec 15 15:58:05 GMT 2023
|
PRIMARY | |||
|
300000042391
Created by
admin on Fri Dec 15 15:58:05 GMT 2023 , Edited by admin on Fri Dec 15 15:58:05 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |